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14.50 and 69.07 ± 8.28 years, and average length of stay for 9.41 ± 4.45 and 9.17 ± 
4.55 days, respectively. Most procedures were conducted at medical centers (45.52% 
and 37.57%). The most frequent diagnoses for THR are avascular necrosis (45.22%) 
and osteoarthritis (44.05%); while for TKR is osteoarthritis (96.42%). Only 40 THR 
(3.90%) and 160 TKR (6.66%) had ever been prescribed antithrombotic agents after 
surgeries, and mostly used aspirin alone (18 THR and 95 TKR). CONCLUSIONS: 
According to this nationwide individual patient dataset, antithrombotic agents are not 
commonly used after THR and TKR in Taiwan, but aspirin is the most frequently 
prescribed of all. These ﬁ ndings deviate from the recommendations of current inter-
national guidelines. To establish Taiwanese own guidance, it is necessary to further 
investigate the effectiveness and safety of prophylactic antithrombotic agents after 
THR and TKR, and explore the inﬂ uences of reimbursement policy and genetic factors 
on these outcomes. 
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ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS OF THE 
MALAYSIAN COMMUNITY PHARMACISTS REGARDING 
PHARMACOVIGILANCE: FINDINGS FROM AN INTERVENTIONAL STUDY
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OBJECTIVES: To assess the knowledge and perception of community pharmacists in 
Malaysia toward reporting of adverse drug reactions (ADRs). METHODS: A cross-
sectional study employing pre and post intervention design was undertaken with a 
sample of 42 community pharmacists to explore their knowledge of and the perception 
toward the pharmacovigilance and ADRs reporting. Changes in scores before and 
after the completion training program in knowledge and perception were measured. 
Statistical analysis: The data were analyzed by using SPSS version 17.0 software 
package (SPSS Inc., Chicago, IL, USA). Both descriptive and inferential statistics were 
used when ever appropriate. Frequencies and percentages were used to describe the 
respondents’ demographic information and professional characteristics. Wilcoxon 
Signed ranks test, Paired sample t test and The McNemar χ2 test were applied to 
compare the differences in knowledge and perception before and after the educational 
program whenever appropriate. RESULTS: Forty-two community pharmacists (CPs) 
were enrolled in this study. A comparison of CPs knowledge before and immediately 
after implementation the education program showed signiﬁ cant differences, the par-
ticipated community pharmacists’ mean scores in knowledge of pharmacovigilance 
and adverse drug reactions reporting signiﬁ cantly increased compared to the baseline 
(z = −5458, N = 42 P < 0.001). Following the intervention, only few (3, 7.2%) 
respondents reported that they do not have any ideas on how to report ADR to the 
relevant authorities in Malaysia. Upon completion of the education program, a large 
proportion of the pharmacists (45%) believed that they were conﬁ dent in their knowl-
edge in detection and performing ADRs reporting (z = −2.866, N = 42, P = 0.004). 
CONCLUSIONS: The ﬁ nding of the study indicates the need for designing educational 
programs for the community pharmacists, in order to improve the level of knowledge 
toward the pharmacovigilance and ADRs reporting process locally. 
DU4
COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY 
FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE 
(T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY 
LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR 
PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR 
HYPERTENSION IN MALAYSIA AND INDIA
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OBJECTIVES: To assess the cost-effectiveness of T-TTFC compared with L-LTFC 
treatment sequences for patients with open angle glaucoma or ocular hypertension 
(OHT) using a payer perspective in Malaysia and India. METHODS: A Markov model 
simulated the disease progression of open angle glaucoma and ocular hypertension 
(OHT) patients in India and Malaysia. Transition probabilities were obtained from 
Denis (2008), and extrapolated from two phase III clinical trials (Topouzis, 2007; 
Netland; 2001). Probabilities to develop new visual ﬁ eld defect (VFD) was estimated 
from literature (Denis, 2004). Utilization patterns were derived from local hospitals 
and literature. Unit costs were obtained from list prices. The time horizon was 5 years 
and sensitivity analyses were performed on key parameters. RESULTS: At 5 years, 
fewer T-TTFC patients switched to third line treatment, and 65.5% of patients showed 
no disease progression (no new VFDs) compared to 61.4% for L-LTFC Thus initiation 
of treatment in an OHT patient with T followed by TTFC if needed would avoid one 
incidence of VFD in every 24 incident cases (Number Needed to Treat—NNT). In 
Malaysia, T-TTFC results in a cost-savings of 1286 RM (US$378) against L-LTFC. 
In India over a 5-year period, T-TTFC results in a cost savings of 11,184 INR 
(US$243) against L-LTFC. Sensitivity analyses have demonstrated the robustness of 
these ﬁ nding. CONCLUSIONS: From the payer perspective, T-TTFC yielded cost-
savings and fewer treatment switches. Poor IOP control results in therapy changes and 
increases the probability of patients experiencing new VFDs (Denis 2004), which in 
turn adversely impacts patient quality of life. Our savings estimates are conservative 
because potential cost savings, as a consequence of fewer ophthalmologist visits, 
particularly for patients who use private healthcare facilities, have not been captured. 
With these ﬁ ndings policy-makers and clinicians should consider the use of T-TTFC 
for glaucoma patients as potential cost-saving medications. 
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A CROSS-COUNTRY COMPRASION OF HEALTH PERFORMANCE 
BETWEEN TAX-FUNDED AND SOCIAL HEALTH INSURANCE SYSTEM: 
THE CHANNEL VIA PREVENTIVE CARE
Chen Q, Li L
Peking University, Beijing, China
OBJECTIVES: Tax-funded system and the social health insurance (SHI) system are 
two main choices for health-care system reform. This research investigates the differ-
ences of health outcome and health expenditure between these two systems. The 
channels of such differences are also valuable for policymaker. We further explore the 
channel via public health and preventive care investment that leads to these differences. 
We are also interested in the impact of ﬁ scal and political decentralization on health 
systems. METHODS: We merge the data from a variety of sources including WHO, 
the World Bank, OECD together with database prepared by independent researchers 
like Polity IV and Government Performance Indicator. After controlling the variables 
indicating the social-economic situations, we implement the Pooled-OLS Method and 
Fix-Effect Method for panel data. Then check the model speciﬁ cation by testing the 
autocorrelation of the residuals. RESULTS: When the share of SHI in public health 
expenditure increases, the total health expenditure (THE) measured as its share in 
GDP increase dramatically. However, if there is local responsibility, this negative 
impact will be mitigated. What’s more, the increase of SHI share also plays down the 
life expectancy, but with local responsibility the negative impact can get amended. It 
is worth the attention that the public health performance, measured by the share of 
expenditure in THE and a series of public health behaviors including the immunization 
rates and infectious disease incidences, presents a consistent pattern. That is, with the 
increase of the SHI share, the public health performance is weakened, but with local 
responsibility, the performance will be improved to some extent. CONCLUSIONS: 
Tax-funded system is more efﬁ cient in the sense of cost-beneﬁ t, and public health and 
preventive care investment are important channels of these different performances 
between the two types of health-care system. 
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OBJECTIVES: The aim of this paper is to investigate whether the adoption of phar-
maceutical innovation increases the overall expenditure on health care by focusing on 
diabetic patients. METHODS: By examining the National Health Insurance sampling 
longitudinal claims data between 2000 and 2004, we use a new class of drugs, namely, 
thiazolidinediones (TZD), as an example to investigate the effect on health expenditure 
of prescribing new drugs to patients by decomposing the impact into treatment sub-
stitution and treatment expansion effects. The difference-in-difference approach was 
used to estimate the effects of adopting new drugs by comparing the difference between 
the users of TZD drugs (the treatment group) and the nonusers of TZD drugs (the 
control group) as well as the difference between the pre and post periods. RESULTS: 
Our results indicate that the introduction of new drugs mainly impacts the outpatient 
drug expenditure and does not give rise to any offsetting effect on other outpatient 
and inpatient health expenditures. This suggests that the adoption of pharmaceutical 
innovation in treating diabetic patients is expenditure-increasing. In addition, we ﬁ nd 
evidence that the treatment substitution channel has a more signiﬁ cant impact on 
health expenditure than the treatment expansion channel. CONCLUSIONS: An 
important policy implication for our ﬁ nding is that new prescription drugs do not pay 
for themselves, suggesting that the justiﬁ cation for increasing health expenditure on 
the treatment of diabetes is not conditional upon a lowering in the demand for other 
types of health-care services. By contrast, it is conditional upon the increased health 
beneﬁ ts per se. 
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RISK SHARING SCHEME: OMALIZUMAB ADAPTATION IN KOREA
Kim S, Kim J, Kim J, Kim C, Shin K, Kim K, Kim H
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OBJECTIVES: The innovative but expensive biologic agents are introduced in recent 
years, Korea government is meeting with difﬁ culty in funding for these agents due to 
limited health-care budget. Pay for performance as risk sharing scheme has been 
adopted to overcome this situation in other countries. In this article we tried to ﬁ nd 
an affordable price based upon a budget neutral concept and adapted to risk sharing 
of Omalizumab. METHODS: Omalizumab, for treatment of moderate to severe 
allergic asthma, is only treated for responders at 16 weeks. We modeled the perfor-
mance-based risk sharing along four assumptions: 1) no additional national health-
care budget, budget of risk sharing ≤ budget of no risk sharing; 2) positive 
manufacturer’s proﬁ t; 3) reimbursed only for responders at 16 weeks; and 4) manu-
facturer funding to responder in screening period. We also simulated the model by 
changing of input parameters. RESULTS: We deﬁ ned and analyzed the function of 
risk sharing scheme based on national health-care budget and manufacturer’s proﬁ t. 
Lower boundary of affordable price was derived from the minimum of acceptable 
predicted sales volume for manufacturer and upper was calculated by a point of budget 
neutral. Lower boundary was highly depends on unit selling price, production cost 
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and projected vials. Upper boundary was inﬂ uenced more by total target patients, 
response rate, and expected price with no risk sharing. CONCLUSIONS: The concept 
of performance-based payment is a risk sharing between the payer and manufacturer 
for high-quality of new agent, and improves to patient’s quality of life within the 
available national health-care budget. We show that the range of affordable price is 
calculated by a manufacturer’s proﬁ t and neutral point of health-care budget in the 
performance-based risk sharing and discuss potential challenges. 
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OBJECTIVES: To control the high pharmaceutical expenditure, the Bureau of 
National Health Insurance introduced the generic grouping method to reduce price 
variation among off-patent drugs since 2000. The purpose of this study was to 
examine the effect of the price adjustments on the trend of pharmaceutical expendi-
ture. METHODS: We used BNHI monthly claim data from 1999 to 2007 and 
incorporated drug registry ﬁ le, drug price ﬁ le and 2009 WHO ATC/DDD ﬁ le. To 
further analyze the effect of generic grouping, we classiﬁ ed the branded drug into three 
categories patented branded drug, off-patent branded drug with no competitive 
generic drug and off-patent branded drug with competitive drug. RESULTS: We found 
that from 1999 to 2007, the annual growth rate of pharmaceutical expenditure was 
6.0%; outpatient 6.3% and inpatient 5.5%. During the study period, the sales of the 
patented branded drugs rose from 20.5% to 30.9% with the highest increasing rate. 
The sales of the off-patent branded with competitive generic drugs and generic without 
the BA/BE testing drugs fell from 21.1% to 18.6% and from 39.3% to 28.4%, 
respectively. The sales volume in terms of DDD also has the same pattern as the drugs 
sales. Regarding the impact of drug price adjustment on Hospital, we found the share 
of drug claim by medical centers rose from 35.5% to 41.3%; regional hospitals from 
25.3% to 30.2%, however local hospitals and primary health care decreased their 
share. In terms of ﬁ rms, the IRPMA group held the highest increasing rate on share 
and importers held the lowest. CONCLUSIONS: The generic grouping price adjust-
ment policy has effectively reduced the off-patent branded drug expenditure. However, 
total drug expenditure didn’t decrease due to the increased expenditure of the new 
drugs with high prices. 
POSTER SESSION
CANCER – Clinical Outcomes Studies
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THE EVALUATION OF ADR ONLINE REPORTING OF RADIOPAQUE 
AGENTS IN A UNIVERSITY HOSPITAL IN TAIWAN
Huang CY, Hsieh YW, Lin WL, Wu HC
China Medical University Hospital, Taichung, Taiwan
OBJECTIVES: Radiopaque agents induce ADR frequently. But the numbers of ADR 
reporting are less than actual happening because of heavy workload on medical staffs. 
We created a simple and convenient online reporting system to replace paper report 
in our hospital. The aim of this study was to assess the variation of reporting rate. 
METHODS: In the system, the cases reported by physician including medication used, 
time of ADR come up and description of ADR event. We downloaded the data of 
patients who administrated radiopaque agents retrospectively as the base of study 
group, and observed the reporting rate of online reporting system from 2008 July to 
2009 June (i.e., intervention group), comparing it with the paper report in 2007. 
RESULTS: There are ﬁ ve radiopaque agents with four nonionic and 1 ionic contrast 
media (e.g., Gadobenate Dimeglumine, Iodixanol, Iohexol, Ioversol and Urograﬁ n) 
used in our hospital. We received 20 ADR reports within 22,754 prescriptions of 
radiopaque agents from January to December in 2007 and 62 ADR reports in 29,840 
prescriptions from 2008 July to 2009 June. The reporting rate elevated 2.3 times 
(0.09% to 0.21%) when we shifted paper reporting to online reporting system. In the 
intervention group, more than half ADR reports were rash and no serious side effects 
(e.g., nephrotoxicity, anaphylactic shock) had been reported. CONCLUSIONS: ADR 
report is important in patient safety and pharmacovigilance issues. In clinical practice, 
staff may miss to report ADR because of enormous amount of work load. If the 
reporting system is more user-friendly, it would be closer to the true incidence of 
adverse events which have been reported. 
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OBJECTIVES: Narcotic analgesic was usually used to relieve cancer pain in the past 
decades. Recently, co-analgesics with adjuvant drugs have become an essential way 
and successful alternatives for holistic care. The aim of this study is to assess the 
outcome of using cancer pain adjuvants. METHODS: This is an observational study. 
Cancer patients with pain score > 3 were recruited from three medical centers in 
Taiwan. Numeric Pain Rating Scale, Wong-Baker Face Pain Rating Scale and Brief 
Pain Inventory were used to evaluate the differences of pain control between two 
groups, addition of pain adjuvants and narcotics. The monthly consumption of narcot-
ics, the frequency of breakthrough pain and adverse event were recorded for analysis 
by Paired t-test. RESULTS: A total of 120 patients were eligible in this study. Fifty-ﬁ ve 
(45.8%) and 65 (54.2%) patients received narcotic analgesics and pain adjuvants for 
pain control, respectively. The satisfaction of patients in both groups on pain control 
improved 2.03 ± 1.87 points in the narcotics group and 2.14 ± 1.72 points in con-
comitant adjuvants group without signiﬁ cant difference. (F1,118 = 0.1024, P = 0.7495) 
The times of breakthrough pain was signiﬁ cantly decreased in adjuvants group as 
compared to narcotics group(−1.47 ± 2.23 vs. −0.48 ± 1.80; F1,118 = 7.3556, P = 
0.0077). CONCLUSIONS: No signiﬁ cant difference in total consumption of narcotics 
and pain control was founded. The frequency of breakthrough pain is likely to be 
improved in the concomitant adjuvants as compared in the narcotics group. The study 
found the safety of adjuvant therapy do no harm to palliative patients. 
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OBJECTIVES: Cholangiocarcinoma is a leading cause of cancer death in the North-
east of Thailand. Currently, chemotherapy and supportive care are the main treat-
ments in non-resectable cholangiocarcinoma patients. Many adverse events (AE) from 
disease and treatments have been reported that affect quality of life (QOL) of the 
patients. This study evaluated the efﬁ cacy of melatonin compared to placebo on the 
QOL, AE and survival time. METHODS: The study was a randomized, double-blind, 
placebo, controlled trial. The patients received treatment following the protocol of 
each hospital, and the study drug. Patients were randomized by mixed-block random-
ization stratiﬁ ed by hospital and type of treatment. The treatment group received 
melatonin (20 mg/day) and the control group received placebo. Patients started taking 
the study drug on the ﬁ rst day of the treatment and continued for 3 months. QOL 
was assessed using Thai Functional Assessment of Cancer Therapy-Hepatobiliary 
(FACT-HEP) and AE were assessed using Common Toxicity Criteria Adverse Events 
(CTCAE). RESULTS: There were 30 patients recruited in the study, divided into 15 
patients in each group. Baseline characteristics of the two groups were not different. 
The melatonin group had a higher but not signiﬁ cant percentage of improvement in 
FACT-Hep scores than the control in both the ﬁ rst (20% vs. 6.7%) and second (20% 
vs. 6.7%) month. Median survival was longer in the melatonin group (160 vs. 130 
days, P > 0.05). In addition, there were fewer reports of Grade 3–5 AE in the melatonin 
group than placebo in terms of anorexia (11% vs. 50%), fatigue (11% vs. 50%), 
nausea/vomiting (0% vs. 10%) and weight loss (0% vs. 20%). CONCLUSIONS: The 
combination of melatonin with standard treatment did not prolong overall survival. 
However, the melatonin treatment can decrease AE and maintain quality of life of 
non-resectable cholangiocarcinoma patients. Further studies with larger samples are 
needed. 
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CANCER SYMPTOM SURVEY AND RELIABILITY ANALYSIS
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OBJECTIVES: Through symptom survey in cancer patients to ﬁ nd out the symptom 
distribution and patients treatment require. Also validate set of symptom items that 
are most commonly used in Traditional Chinese Medicine (TCM). METHODS: Use 
M. D. Anderson Symptom Assessment Inventory (MDASI) that previously validated 
Chinese version. Add 10 TCM items. We also asked the questions about using TCM 
request in cancer care. A multi center cross-sectional study using a convenience sample 
of 340 patients were conducted in 3 hospitals in Beijing and Dalian. Statistical use 
Spss and Excel software. Self evaluate questioner with Cronbach’s Alpha score. 
RESULTS: The most severe symptoms were fatigue 89.4%, sleeping disturbance 
74.4%, moth drier 72.9%, and poor appetite 72.9%, forgotten 71.2%. The inﬂ uence 
of cancer symptoms to work, mood and activity were 89.7%, 82.6%, 78.6% sepa-
rately. The quality of life was affected severely. 80% patients want to regulate the 
body with TCM. Almost 100% patients hope to know the knowledge of integrated 
TCM and western medicine, and the effect of TCM treatment cancer and health 
recover. Cronbach’s Alpha score indicated acceptable internal consistency both the 
MDASI and TCM items, 0.86 for MDASI, 0.78 for TCM, 0.9 for MDASI_TCM 23 
items. CONCLUSIONS: Fatigue, sleep disturbance, moth drier, poor appetite and 
forgotten are more severe symptoms in our cancer patient’s survey. Greatly affect the 
quality of life of patients. There are an extremely request that TCM holism regulation 
in cancer patients. The MDASI and its TCM model could a critical tool to measure 
the effectiveness of TCM in cancer symptom management. 
